---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Corticosteroids"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Corticosteroids. Topics: Guideline recommendation for initial treatment, Certainty of randomized evidence for corticosteroids, Pulsed dexamethasone versus daily prednisolone: remission at 12 months, Long-term remission after corticosteroid courses, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/corticosteroids"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Corticosteroids

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Corticosteroids

<a id="topic-2.2.2.1.1-1"></a>

### Guideline recommendation for initial treatment

> “(a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.1-2"></a>

### Certainty of randomized evidence for corticosteroids

> “One non‐blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review.”
> “Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low‐quality evidence).”
> “There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate‐quality evidence), or change in disability or impairment after one year (low‐quality evidence).”
> “Nevertheless, corticosteroids are commonly used in practice, supported by very low‐quality evidence from observational studies.”

Source: [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

<a id="topic-2.2.2.1.1-3"></a>

### Pulsed dexamethasone versus daily prednisolone: remission at 12 months

> “The primary outcome measure was remission at 12 months, defined as improvement of at least three points on the Rivermead mobility index and improvement of at least one point on the inflammatory neuropathy cause and treatment disability scale.”
> “Between December, 2003, and December, 2008, 40 patients were treated: 24 received dexamethasone and 16 received prednisolone. At 12 months, 16 patients were in remission: ten in the dexamethasone group and six in the prednisolone group (odds ratio [OR] 1.2, 95% CI 0.3-4.4).”
> “Most adverse events were minor and did not differ substantially between treatment groups; however, sleeplessness and Cushing's face occurred more often in the prednisolone group.”

Source: [van Schaik et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20133204/)

<a id="topic-2.2.2.1.1-4"></a>

### Long-term remission after corticosteroid courses

> “Cure (>5 years off treatment) or remission according to the CDAS criteria after 1 or 2 courses of pulsed dexamethasone or daily prednisolone was achieved in 10 out of 39 patients (26%).”
> “Half of the patients who were in remission after initial treatment experienced a relapse (median treatment-free interval: 17.5 months for dexamethasone, 11 months for prednisolone).”

Source: [Eftimov et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22442436/)

<a id="topic-2.2.2.1.1-5"></a>

### Intravenous methylprednisolone versus intravenous immunoglobulin over 6 months

> “More patients stopped methylprednisolone (11 [52%] of 21) than IVIg (three [13%] of 24; relative risk 0·54, 95% CI 0·34-0·87; p=0·0085).”
> “Reasons for discontinuation were lack of efficacy (eight in the methylprednisolone group vs three in the IVIg group), adverse events (one in the methylprednisolone group), or voluntary withdrawal (two in the methylprednisolone group).”
> “After therapy discontinuation, more patients on IVIg worsened and required further therapy (eight [38%] of 21) than did those on methylprednisolone (none of ten; p=0·0317).”

Source: [Nobile-Orazio et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22578914/)

<a id="topic-2.2.2.1.1-6"></a>

### Oral prednisolone versus intravenous immunoglobulin: randomized crossover trial

> “This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 mg daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).”
> “Twenty-four of the thirty-two randomized patients completed both treatment periods.”
> “There was slightly, but not significantly, more improvement after IVIg than with prednisolone, the mean difference between the groups in change in disability grade being 0.16 (95% CI = -0.35 to 0.66).”
> “A serious adverse event (psychosis) attributable to treatment occurred in one patient while on prednisolone and in none with IVIg.”

Source: [Hughes et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11506402/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
